<DOC>
	<DOCNO>NCT01521585</DOCNO>
	<brief_summary>The principal aim study obtain safety tolerability data SEN0014196 administer orally 12 week male female patient Huntington 's Disease .</brief_summary>
	<brief_title>A Phase II Safety Tolerability Study With SEN0014196</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Genetically confirm , manifest HD ( CAG repeat length ≥ 36 ) motor sign HD ( include motor score UHDRS ≥ 5 ) . Clinical Stages I III ( Total Functional Capacity Subscale Score [ TFC ] ≥ 3 ) . Patients must anticipate ambulatory able attend outpatient visit duration study . Patients must age ≥ 30 year ≤ 70 year . Body mass index 18 31 kg/m2 inclusive , body weight great 50 kg . Patients must able give informed consent legal representative consent behalf . Patients must able comply trial procedure . Patients must clinically significant relevant medical psychiatric history could affect conduct study evaluation data , ascertain Investigator detail medical history screen assessment . Male patient must agree use condom entire duration study 3 month follow last dose study drug . Females childbearing potential ( last menses less 1 year prior enrolment ) . Participation study investigational drug within 30 day Baseline Visit . Any prior concomitant use Class I Class II histone deacetylase ( HDAC ) inhibitor Zolinza®/vorinostat belinostat . Clinical evidence significant unstable medical illness Investigator 's judgement , include screen transaminase ( AST ALT ) ≥ 3 time upper limit normal ( ULN ) , estimate GFR &lt; 60 mL/min , unexplained proteinuria microscopic haematuria uncontaminated sample obtain Screening confirm repeat testing . QTcF interval &gt; 450 m men &gt; 470 ms woman PR &gt; 220 m , clinically relevant abnormal ECG finding Women pregnant breastfeeding . Clinically significant abnormality screen laboratory study , opinion Investigator , would interfere participation study . Current evidence history ( within 1 year baseline ) psychosis , hallucination delusion , include major depression psychotic feature , define DSMIVTR . Patients currently experience mild depression , moderate depression adequately appropriately treated judgment Investigator , participate depression expect interfere study participation . Suicide risk , determine meeting follow criterion : A suicide attempt within past year suicidal ideation within 60 day Baseline Visit ( Day 1 ) . Significant risk suicide , judge Principal Investigator , base psychiatric interview information collect CSSRS . Current diagnosis history ( within 1 year baseline ) alcohol substance abuse ( except nicotine caffeinerelated disorder ) define DSMIVTR . Known allergy ingredient study drug ( active and/or placebo ) . A history malignancy type within 2 year prior screen . A history surgically excise nonmelanoma skin cancer permit . Any relevant condition , behaviour , laboratory value , concomitant medication , opinion Investigator , make patient unsuitable entry study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>